Latest Innovation News

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Hancock & Gore is rebranding as Schoolblazer Limited following its acquisition of Trutex, consolidating its global school uniform operations and targeting over $200 million in revenue by FY27.

Hancock & Gore reports a statutory loss for FY25 amid major acquisitions and strategic transformation, setting sights on $200m revenue by FY27 as it rebrands to Schoolblazer Limited.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Select Harvests Limited delivered a robust FY2025 with net profit soaring to $31.8 million and net debt slashed by over 50%, despite a smaller almond crop. Strategic investments in processing and sales underpin a confident outlook.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Nimy Resources has partnered with CSIRO under the Kick-Start program to advance gallium exploration at its Mons Project in Western Australia, leveraging cutting-edge machine learning and scientific expertise.

Synertec has secured a pivotal contract to supply its zero-emission Powerhouse system to Shell QGC’s Coal Seam Gas operations in Queensland, marking a significant step in industrial decarbonisation.